Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on August 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). New severance program covers U.S. employees, increasing retention protection and potential change-in-control transaction costs.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- New severance program covers U.S. employees, increasing retention protection and potential change-in-control transaction costs
- CEO Gaurav Shah receives $674,856 base salary and 60% target bonus
- General Counsel Martin Wilson receives $547,313 base salary and 45% target bonus
- CEO change-in-control severance: 18 months’ salary, target and prorated bonuses, plus 18 months’ COBRA premiums
- Wilson and COO Christopher Stevens receive 12 months’ salary, target and prorated bonuses, plus 12 months’ COBRA premiums around a change in control
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.